Phase 1b trial of anti-EGFR antibody JMT101 and Osimertinib in EGFR exon 20 insertion-positive non-small-cell lung cancer

Phase 1b trial of anti-EGFR antibody JMT101 and Osimertinib in EGFR exon 20 insertion-positive non-small-cell lung cancer

Abstract EGFR exon 20 insertion (20ins)-positive non-small-cell lung cancer (NSCLC) is an uncommon disease with limited therapeutic options and dismal prognosis. Here we report the activity, tolerability, potential mechanisms of response and resistance for dual targeting EGFR 20ins with JMT101 (anti...

Full description

Bibliographic Details
Main Authors: Shen Zhao, Wu Zhuang, Baohui Han, Zhengbo Song, Wei Guo, Feng Luo, Lin Wu, Yi Hu, Huijuan Wang, Xiaorong Dong, Da Jiang, Mingxia Wang, Liyun Miao, Qian Wang, Junping Zhang, Zhenming Fu, Yihua Huang, Chunwei Xu, Longyu Hu, Lei Li, Rong Hu, Yang Yang, Mengke Li, Xiugao Yang, Li Zhang, Yan Huang, Wenfeng Fang
Format: Article
Language:English
Published: Nature Portfolio 2023-06-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-023-39139-4

Internet

https://doi.org/10.1038/s41467-023-39139-4

Similar Items